Immunologic Factors: all 3,292 studies that test it

Page 8 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.

• CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to ChemotherapyCompletedNCT02013817Phase 2Results posted
• Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT02011113Phase 2Results posted
• A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD TherapyCompletedNCT02006706Phase 3Results posted
• A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple MyelomaTerminatedNCT01999335Phase 1Results posted
• A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's LymphomaCompletedNCT01998893Phase 2Results posted
• Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.CompletedNCT01996865Phase 3Results posted
• Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin LymphomaCompletedNCT01995669Phase 1/2Results posted
• A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's LymphomaCompletedNCT01992653Phase 1/2Results posted
• Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By SurgeryCompletedNCT01989572Phase 3Results posted
• MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for LymphomaCompletedNCT01987505Phase 3Results posted
• Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular LymphomaCompletedNCT01980654Phase 2Results posted
• Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref MyelomaTerminatedNCT01979276Phase 1/2Results posted
• A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/LymphomaCompletedNCT01973387Phase 3Results posted
• Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin LymphomaTerminatedNCT01973062Phase 2Results posted
• Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary FibrosisCompletedNCT01969409Phase 2Results posted
• Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency DiseasesCompletedNCT01963143Phase 3Results posted
• Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell LymphomaActive, not recruitingNCT01959698Phase 1Results posted
• Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid ArthritisTerminatedNCT01955733Phase 3Results posted
• Effect of Natalizumab on Infarct Volume in Acute Ischemic StrokeCompletedNCT01955707Phase 2Results posted
• Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular LymphomaCompletedNCT01950273Phase 1Results posted
• Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT01946152Phase 1/2Results posted
• Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)CompletedNCT01938001Phase 3Results posted
• Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)TerminatedNCT01927718Not applicableResults posted
• Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)TerminatedNCT01924169Phase 2Results posted
• Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody TherapyCompletedNCT01922921Phase 1/2Results posted
• Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid MalignanciesCompletedNCT01919619Phase 2Results posted
• Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple MyelomaCompletedNCT01919086Phase 2Results posted
• A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)CompletedNCT01889069Phase 3Results posted
• Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT01886872Phase 3Results posted
• Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple MyelomaTerminatedNCT01881789Phase 1/2Results posted
• Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive RegimenTerminatedNCT01856257Phase 2Results posted
• Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell LymphomaActive, not recruitingNCT01856192Phase 2Results posted
• Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary AtresiaCompletedNCT01854827Phase 1/2Results posted
• Non-Myeloablative Conditioning and Bone Marrow TransplantationActive, not recruitingNCT01850108Not applicableResults posted
• IVIg Efficacy Study to Treat Cutaneous Lupus ErythematosusCompletedNCT01841619Early Phase 1Results posted
• WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell TransplantationCompletedNCT01827137Phase 1/2Results posted
• Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01816971Phase 2Results posted
• Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT01812005Phase 2Results posted
• Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord TransplantationCompletedNCT01810588Phase 2Results posted
• Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasTerminatedNCT01805037Phase 1/2Results posted
• Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical ProstatectomyCompletedNCT01804712Early Phase 1Results posted
• A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin LymphomaCompletedNCT01796171Phase 1/2Results posted
• Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With LenalidomideCompletedNCT01794039Phase 2Results posted
• Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)CompletedNCT01782963Phase 2Results posted
• Renal Allograft Tolerance Through Mixed ChimerismCompletedNCT01780454Phase 1/2Results posted
• Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom MacroglobulinemiaTerminatedNCT01779167Phase 2Results posted
• Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic AnemiaCompletedNCT01772420Phase 2Results posted
• Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and MyelomaCompletedNCT01755975Phase 1/2Results posted
• Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLLCompletedNCT01754857Phase 2Results posted
• Bendamustine + Pomalidomide + Dex in R/R Multiple MyelomaActive, not recruitingNCT01754402Phase 1/2Results posted
• Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)CompletedNCT01753570Phase 3Results posted
• A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic PolyangiitisCompletedNCT01750697Phase 2Results posted
• Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid LeukemiaCompletedNCT01743859Phase 2Results posted
• Long-Term Study of IGIV, 10% in Alzheimer´s DiseaseTerminatedNCT01736579Phase 3Results posted
• Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT01734928Phase 3Results posted
• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasTerminatedNCT01732913Phase 3Results posted
• Belatacept Early Steroid Withdrawal TrialCompletedNCT01729494Phase 4Results posted
• Velcade + Cyclophosphamide in Newly Diagnosed Multiple MyelomaTerminatedNCT01729338Phase 2Results posted
• Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01729091Phase 2Results posted
• A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphomaCompletedNCT01724177Phase 2Results posted
• A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3aCompletedNCT01724021Phase 3Results posted
• Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus LenalidomideCompletedNCT01723839Phase 2Results posted
• Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01718743Phase 2Results posted
• Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell LymphomaCompletedNCT01718691Phase 2Results posted
• Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple MyelomaCompletedNCT01712789Phase 3Results posted
• Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)CompletedNCT01704781Phase 1/2Results posted
• Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's DiseaseCompletedNCT01702961Not applicableResults posted
• Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDSCompletedNCT01700673Phase 2Results posted
• A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01698801Phase 2Results posted
• Rituximab Vasculitis Maintenance StudyCompletedNCT01697267Phase 3Results posted
• A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT01691898Phase 1/2Results posted
• Pomalidomide for Chronic Graft-versus-Host DiseaseCompletedNCT01688466Phase 2Results posted
• Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid ArthritisTerminatedNCT01682512Phase 3Results posted
• Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone LymphomaCompletedNCT01682044Phase 2Results posted
• Lenalidomide Maintenance Therapy for Multiple MyelomaTerminatedNCT01675141Phase 2Results posted
• Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in LymphomaCompletedNCT01665768Phase 2Results posted
• CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid MalignanciesCompletedNCT01664910Phase 1/2Results posted
• Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell LymphomaActive, not recruitingNCT01661881Phase 2Results posted
• Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)CompletedNCT01651039Phase 2Results posted
• A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell LymphomaCompletedNCT01649856Phase 3Results posted
• Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic LeukemiaTerminatedNCT01649791Not applicableResults posted
• Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01645930Phase 1Results posted
• Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)CompletedNCT01643928Not applicableResults posted
• UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple MyelomaCompletedNCT01621672Phase 3Results posted
• T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic TransplantTerminatedNCT01621477Phase 2Results posted
• Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple MyelomaCompletedNCT01615029Phase 1/2Results posted
• Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid TissueCompletedNCT01611259Phase 2Results posted
• Revlimid® as Consolidation Treatment Chronic Lymphocytic LeukemiaTerminatedNCT01600053Phase 2Results posted
• Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous SystemTerminatedNCT01596127Phase 1/2Results posted
• A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney TransplantationCompletedNCT01594424Phase 1/2Results posted
• Rituximab in IgG4-RD: A Phase 1-2 TrialCompletedNCT01584388Phase 1/2Results posted
• Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)CompletedNCT01581593Phase 3Results posted
• Rituximab in Pretreated Elderly or Unfit B-CLL PatientsCompletedNCT01576588Phase 2Results posted
• Maintenance Lenalidomide in LymphomaCompletedNCT01575860Phase 1/2Results posted
• A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGSCompletedNCT01573533Phase 2Results posted
• Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple MyelomaCompletedNCT01572480Phase 2Results posted
• A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL AmyloidosisCompletedNCT01570387Phase 1/2Results posted
• Comparison of Rituximab Induction Therapy Followed by Glatiramer AcetateCompletedNCT01569451Phase 2Results posted
• A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated MyelopathyTerminatedNCT01561755Phase 4Results posted
• A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's DiseaseCompletedNCT01561053Phase 2/3Results posted

← Immunologic Factors overview